Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 41,623 |
|
|||||
| News | - | ||||||
| Day High | 18.82 | Low High |
|||||
| Day Low | 18.15 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Xencor Inc | XNCR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.55 | 3.02% | 18.76 | 10:23:48 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 18.18 | 18.15 | 18.82 | 18.21 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 646 | 41,623 | $ 18.52 | $ 770,772 | - | 16.49 - 28.96 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:23:49 | 70 | $ 18.76 | USD |
Xencor Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.15B | 61.12M | - | 168.34M | -126.09M | -2.06 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Xencor News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XNCR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 19.60 | 19.60 | 17.945 | 18.65 | 547,083 | -0.84 | -4.29% |
| 1 Month | 22.15 | 22.70 | 17.945 | 20.52 | 533,415 | -3.39 | -15.30% |
| 3 Months | 20.38 | 26.84 | 17.945 | 22.02 | 703,728 | -1.62 | -7.95% |
| 6 Months | 18.16 | 26.84 | 16.49 | 20.97 | 621,476 | 0.60 | 3.30% |
| 1 Year | 28.75 | 28.96 | 16.49 | 21.87 | 472,033 | -9.99 | -34.75% |
| 3 Years | 44.64 | 44.80 | 16.49 | 26.91 | 361,576 | -25.88 | -57.97% |
| 5 Years | 32.03 | 58.345 | 16.49 | 30.91 | 358,047 | -13.27 | -41.43% |
Xencor Description
| Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates. |
